Base Year
Historical Year
Forecast Year
The global adult malignant glioma therapeutics market size attained a value of USD 2.19 billion in 2023 driven by rising prevalence of cancer disorders. The market is anticipated to grow at a CAGR of 9.2% during the forecast period of 2024-2032 to attain a value of USD 4.85 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America is anticipated to dominate the global market due to the presence of major product manufacturers, high research and development (R&D), growing healthcare expenditure, and trained personnel. Technological innovation is a major market driver in North America. According to the National Library of Medicine, approximately 17,000 new high-grade gliomas (HGG) cases are diagnosed in the United States each year. Primary malignant brain tumours account for approximately 3% of all cancer deaths, the majority (around 80%) of which are HGG . The rise in the incidence of the disease, a strong economy, high diagnosis rate owing to the awareness about healthcare among the population are the other major factors driving the adult malignant glioma therapeutics market.
Due to an increase in government awareness programmes and the number of generic drugs, Asia Pacific is estimated to account for the largest market share for adult malignant glioma therapeutics in the forecast period. The market's growth, however, is likely to be determined by the combined prospects in technology and opportunity in developing Asian countries such as China, Japan, India, and South Korea. The relatively large patient population requiring affordable care and improvements in health care infrastructure in rapidly developing countries that aid in the early detection of malignant gliomas are likely to drive the adult malignant glioma therapeutics market.
Malignant brain tumours have a profound effect on both those who receive and those who deliver the diagnosis. Malignant gliomas, the most prevalent subtype of primary brain tumours, are aggressive, highly invasive, and neurologically damaging tumours that are among the most fatal human diseases.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The different therapies provided by the market are:
Based on disease, the market is divided into:
The end-uses of the market are:
The regional markets for adult malignant glioma therapeutics can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The rising prevalence of cancer-related disorders worldwide and growing cases of brain tumours are the major factors driving the adult malignant glioma therapeutics market. The adoption of an unhealthy lifestyle, genetic modification/alteration, increased age, excessive exposure to radiation and family history with brain cancer are also propelling the market growth. Further, increased advancements in cancer treatment, a fast-expanding pipeline of innovative novel medications, and increased government support to accelerate the process of orphan drug approval are expected to bolster the market growth during the projection period. However, high treatment costs, loss of market exclusivity, post-patent expiration, and price reductions in branded drugs owing to competition from generic brands may impede the market growth.
Technological advancements in diagnosing glioma and analysing its progression through various imaging modalities are accelerating the market growth. For example, researchers have developed a new imaging technique that may help eliminate the malignant tumour from the human body. This imaging method may help surgeons locate the tumour with ease. The method also involves using an infra-red (IR) camera and an imaging reagent tozuleristide (BLZ-100). The agent contains a synthetic version of an amino acid compound found in scorpion venom. The primary goal of this procedure was to distinguish between healthy and tumour tissue. This aids in the retention of healthy tissue following surgery, increasing the overall efficiency of the procedure . Such discoveries are likely to favour the growth of the global adult malignant glioma therapeutics market in the coming years.
The report gives a detailed analysis of the following key players in the global adult malignant glioma therapeutics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diseases Type |
|
| Breakup by Therapy Type |
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Treatment Centers |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
In 2023, the global market for adult malignant glioma therapeutics reached a value of USD 2.19 billion.
The market is anticipated to grow at a CAGR of 9.2% during the forecast period of 2024-2032 to reach a value of USD 4.85 million by 2032.
The major drivers of the market include the growing cases of brain tumours, adoption of an unhealthy lifestyle, excessive exposure to radiation, family history with brain cancer, fast-expanding pipeline of innovative novel medications, increased government support, and technological advancements.
The rising prevalence of cancer-related disorders and increased advancements in cancer treatment are the key industry trends propelling the growth of the market.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The different therapies provided by the market are radiotherapy, chemotherapy, and targeted therapy, among others.
Based on disease, the market is divided into anaplastic astrocytoma, glioblastoma multiforme, and anaplastic oligodendroglioma, among others.
The end-uses of the market are speciality clinics, hospitals, and cancer and radiation therapy centres, among others.
The major players in the industry are Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Arbor Pharmaceuticals, LLC, and AbbVie Inc., among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share